• Regulatory

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery

CEO Update | 25 April 2022

It is great to see our ecosystem back out and about in person this Spring – and especially to be joined by 200 colleagues from across the biotech and life sciences sector at our London Regional event last week. The discussion on funding alternatives to IPO for scaling biotechs was both insightful and inspiring and provoked lots more conversations in the vibrant networking that followed. Read on for updates on WuXi healthcare forum, just published BIA quarterly influence report, Valneva approval and more...

EuropaBio published policy recommendations for the healthcare and industrial biotechnology sectors

EuropaBio has published the National Associations Council Summit 2022 Event Report ''Biotechnology: Delivering Europe’s industrial strategy across the sectors''. The report includes key policy recommendations for healthcare and industrial biotechnology sectors at national and the EU level which could serve the policymakers to get a better understanding of the sector’s potential and regulatory challenges in operating on the national and EU level.

NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.

Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.

CEO Update | 11 April 2022

Last week, we released new data showing that UK biotech companies continue to demonstrate they command the confidence of global venture capital(VC) investors with £453m raised in the first quarter of 2022. The first quarter is the best for UK biotech VC financing ever recorded by BIA and Clarivate and neither the US nor China enjoyed the same year on year growth. The data was covered in this weekend’s Sunday Times with analysis from our Head of Policy and Public Affairs, Dr Martin Turner.

tranScrip accelerates growth and expands service capabilities with key acquisition

tranScrip, the fast-growing contract drug development organisation which supports the development and lifecycle of medicines, has acquired Dublin-based Real Regulatory, a highly respected business specialising in European regulatory affairs, quality systems and compliance for medical products.

Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing

Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines. This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs

BIA analysis of the Spring Statement 2022

The Chancellor made his Spring Statement yesterday announcing a raft of changes across the tax system to address the current economic conditions for people and businesses in the UK. He laid out his vision to grow the economy with a focus on capital, people and ideas, and also provided a useful update on many important areas of tax policy for the life sciences and biotech sector.

CEO Update | 21 March 2022

Many of you will be aware that there have been reports this week from the World Trade Organisation in Geneva that the EU, South Africa, India and the US are agreeing a compromise on the waiver of intellectual property rights on COVID-19 vaccines. The key part of the compromise would be that developing countries that have exported less than 10% of the world’s vaccines in 2021, (so India but not China) would be able to authorise the use of a patented coronavirus vaccine without the patent owner’s consent.

A closer look at the FDA’s approval of Immunocore’s KIMMTRAK

Following the FDA approval of Immunocore's treatment of metastatic uveal melanoma (mUM), KIMMTRAK, guest author Sir John Bell shares what this could mean for the UK life sciences.